{"id":"thymoglobulin-everolimus","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Thymoglobulin works by binding to CD3 receptors on T cells, leading to their depletion and immunosuppression. Everolimus, on the other hand, inhibits the mammalian target of rapamycin (mTOR) pathway, which is involved in cell growth and proliferation. By combining these two mechanisms, Thymoglobulin + Everolimus can effectively suppress the immune system and prevent organ rejection.","oneSentence":"Thymoglobulin is an anti-CD3 monoclonal antibody that depletes T cells, while Everolimus is an mTOR inhibitor that suppresses cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:35.281Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant patients"}]},"trialDetails":[{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT04414735","phase":"NA","title":"Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Kidney Transplant Rejection","enrollment":30},{"nctId":"NCT01976390","phase":"NA","title":"Comparing Everolimus and Sirolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2013-10-01","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT04849533","phase":"PHASE4","title":"Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2021-04-09","conditions":"Kidney Transplant Rejection","enrollment":120},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT01895049","phase":"PHASE4","title":"Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria","status":"COMPLETED","sponsor":"Helio Tedesco Silva Junior","startDate":"2013-08","conditions":"Kidney Transplantation, Cytomegalovirus","enrollment":171},{"nctId":"NCT01354301","phase":"PHASE4","title":"Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2011-05","conditions":"Cytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection","enrollment":300},{"nctId":"NCT01028092","phase":"PHASE3","title":"mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2009-03","conditions":"Renal Transplant","enrollment":327},{"nctId":"NCT01312064","phase":"PHASE4","title":"De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2011-04","conditions":"Renal Insufficiency","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Thymoglobulin + Everolimus","genericName":"Thymoglobulin + Everolimus","companyName":"University Hospital, Brest","companyId":"university-hospital-brest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thymoglobulin is an anti-CD3 monoclonal antibody that depletes T cells, while Everolimus is an mTOR inhibitor that suppresses cell proliferation. Used for Prevention of organ rejection in kidney transplant patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}